Your browser doesn't support javascript.
loading
Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome.
Lebrun-Frénay, Christine; Rollot, Fabien; Mondot, Lydiane; Zephir, Helene; Louapre, Celine; Le Page, Emmanuelle; Durand-Dubief, Françoise; Labauge, Pierre; Bensa, Caroline; Thouvenot, Eric; Laplaud, David; de Seze, Jerome; Ciron, Jonathan; Bourre, Bertrand; Cabre, Philippe; Casez, Olivier; Ruet, Aurélie; Mathey, Guillaume; Berger, Eric; Moreau, Thibault; Al Khedr, Abdulatif; Derache, Nathalie; Clavelou, Pierre; Guennoc, Anne-Marie; Créange, Alain; Neau, Jean-Philippe; Tourbah, Ayman; Camdessanché, Jean-Philippe; Maarouf, Adil; Callier, Celine; Vermersch, Patrick; Kantarci, Orhun; Siva, Aksel; Azevedo, Christina; Makhani, Naila; Cohen, Mikael; Pelletier, Daniel; Okuda, Darin; Vukusic, Sandra.
Afiliación
  • Lebrun-Frénay C; Centre de Resssource et Competence Sclérose En Plaques Nice, Unité Recherche Clinique Cote d'Azur Unité de Recherche sur le Syndrome Radiologique Isolé, Université Nice Côte d'Azur, Neurologie Centre Hospitalier Universitaire Pasteur 2, Nice, France.
  • Rollot F; Centre des Neurosciences de Lyon, Observatoire Français de la Sclérose en Plaques, Institut National de la Santé et de la Recherche Médicale 1028 et Centre National de Recherche Scientifique Unité Mixte de Recherche 5292, Lyon, France Université Claude Bernard Lyon 1, Lyon, France.
  • Mondot L; European Database for Multiple Sclerosis Foundation, Lyon, France.
  • Zephir H; Université Claude Bernard Lyon 1, Faculté de Médecine Lyon Est, Lyon, France.
  • Louapre C; Centre de Resssource et Competence Sclérose En Plaques Nice, Unité Recherche Clinique Cote d'Azur Unité de Recherche sur le Syndrome Radiologique Isolé, Université Nice Côte d'Azur, Neurologie Centre Hospitalier Universitaire Pasteur 2, Nice, France.
  • Le Page E; Université de Lille, Inserm Unité Mixte de Recherche-S 1172 LilNcog, Centre Hospitalier Universitaire Lille, Fédération Hospitalo-Universitaire Precise, Lille, France.
  • Durand-Dubief F; Sorbonne University, Department of Neurology, Assistance Publique des Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
  • Labauge P; Centre Hospitalier Universitaire Pontchaillou, Centre d'Investigation Clinique 1414 Institut National de la Santé et de la Recherche Médicale, Rennes, France.
  • Bensa C; Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France.
  • Thouvenot E; Centre de Ressources et Competences Sclerose En Plaques, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
  • Laplaud D; University of Montpellier, Montpellier, France.
  • de Seze J; Department of Neurology, Fondation Rothschild, Paris, France.
  • Ciron J; Department of Neurology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France; Institut de Génomique Fonctionnelle, Université de Montpellier, Centre National de Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Montpellier, France.
  • Bourre B; Service de Neurologie, Centre d'Investigation Clinique 015 Institut National de la Santé et de la Recherche Médicale, Nantes, France; Institut National de la Santé et de la Recherche Médicale 1064, Nantes, France.
  • Cabre P; Department Clinical Investigation Center, Department of Neurology, Centre Hospitalier Universitaire de Strasbourg, Institut National de la Santé et de la Recherche Médicale 1434, Strasbourg, France.
  • Casez O; Department of Neurology, Centre de Resssource et Competence Sclérose En Plaques, Centre Hospitalier Universitaire de Toulouse; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche1291, Centre Na
  • Ruet A; Department of Neurology, Centre Hospitalier Universitaire de Rouen, Rouen, France.
  • Mathey G; Department of Neurology, Centre Hospitalier Universitaire de la Martinique, Fort-de-France, France.
  • Berger E; Department of Neurology, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.
  • Moreau T; Centre de Resssource et Competence Sclérose En Plaques, Neurology Department, Centre Hospitalier Universitaire of Bordeaux, Bordeaux, France; Université Bordeaux, Institut National de la Santé et de la Recherche Médicale, Neurocentre Magendie, U1215, Bordeaux, France.
  • Al Khedr A; Department of Neurology, Nancy University Hospital, Nancy, France; Université de Lorraine, Equipe Avenir 4360 Adaptation, Mesure et Evaluation en Sante Approches Interdisciplinaires, Vandoeuvre-Lès-Nancy, Nancy, France.
  • Derache N; Department of Neurology, Centre Hospitalier Universitaire de Besançon, Besançon, France.
  • Clavelou P; Department of Neurology, Centre Hospitalier Universitaire de Dijon, EA4184, Dijon, France.
  • Guennoc AM; Department of Neurology, Centre Hospitalier Universitaire d'Amiens, Amiens, France.
  • Créange A; Department of Neurology, Centre Hospitalier Universitaire de Caen Normandie, Caen, France.
  • Neau JP; Department of Neurology, Neuro-Dol, Centre Hospitalier Universitaire Clermont-Ferrand, Université Clermont Auvergne, Institut National de la Santé et de la Recherche Médicale U1107, Clermont-Ferrand, France.
  • Tourbah A; Department of Neurology, Centre Hospitalier Universitaire de Tours, Hôpital Bretonneau, Centre de Resssource et Competence Sclérose En Plaques, Tours, France.
  • Camdessanché JP; Department of Neurology, Assistance Publique des Hôpitaux de Paris, Hôpital Henri Mondor, Université Paris Est, Créteil, France.
  • Maarouf A; Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.
  • Callier C; Department of Neurology, Hôpital Raymond Poincaré, Garches, Unité de Formation de Recherche Simone Veil, Institut National de la Santé et de la Recherche Médicale U1195, Assistance Publique Hopitaux de Paris, Université Paris Saclay, France.
  • Vermersch P; Department of Neurology, Centre Hospitalier Universitaire de Saint-Étienne, Hôpital Nord, Saint-Étienne, France.
  • Kantarci O; Department of Neurology, Centre Hospitalier Universitaire Timone, Marseille, France.
  • Siva A; Centre de Resssource et Competence Sclérose En Plaques Nice, Unité Recherche Clinique Cote d'Azur Unité de Recherche sur le Syndrome Radiologique Isolé, Université Nice Côte d'Azur, Neurologie Centre Hospitalier Universitaire Pasteur 2, Nice, France.
  • Azevedo C; Université de Lille, Inserm Unité Mixte de Recherche-S 1172 LilNcog, Centre Hospitalier Universitaire Lille, Fédération Hospitalo-Universitaire Precise, Lille, France.
  • Makhani N; Mayo Clinic, Rochester, Minnesota.
  • Cohen M; Department of Neurology, Istanbul University Cerrahpasa School of Medicine, Turkey.
  • Pelletier D; University of Southern California, Los Angeles.
  • Okuda D; Departments of Pediatrics and Neurology, Yale School of Medicine, New Haven, Connecticut.
  • Vukusic S; Centre de Resssource et Competence Sclérose En Plaques Nice, Unité Recherche Clinique Cote d'Azur Unité de Recherche sur le Syndrome Radiologique Isolé, Université Nice Côte d'Azur, Neurologie Centre Hospitalier Universitaire Pasteur 2, Nice, France.
JAMA Netw Open ; 4(10): e2128271, 2021 10 01.
Article en En | MEDLINE | ID: mdl-34633424
ABSTRACT
Importance Younger age, oligoclonal bands, and infratentorial and spinal cord lesions are factors associated with an increased 10-year risk of clinical conversion from radiologically isolated syndrome (RIS) to multiple sclerosis (MS). Whether disease-modifying therapy is beneficial for individuals with RIS is currently unknown.

Objectives:

To evaluate the 2-year risk of a clinical event (onset of clinical symptoms of MS) prospectively, identify factors associated with developing an early clinical event, and simulate the sample size needed for a phase III clinical trial of individuals with RIS meeting 2009 RIS criteria. Design, Setting, and

Participants:

This cohort study used data on prospectively followed-up individuals with RIS identified at 1 of 26 tertiary centers for MS care in France that collect data for the Observatoire Français de la Sclérose en Plaques database. Participants were aged 10 to 80 years with 2 or more magnetic resonance imaging (MRI) scans after study entry and an index scan after 2000. All diagnoses were validated by an expert group, whose review included a double centralized MRI reading. Data were analyzed from July 2020 to January 2021. Exposure Diagnosis of RIS. Main Outcomes and

Measures:

Risk of clinical event and associated covariates at index scan were analyzed among all individuals with RIS. Time to the first clinical event was compared by covariates, and sample size estimates were modeled based on identified risk factors.

Results:

Among 372 individuals with RIS (mean [SD] age at index MRI scan, 38.6 [12.1] years), 354 individuals were included in the analysis (264 [74.6%] women). A clinical event was identified among 49 patients (13.8%) within 2 years, which was associated with an estimated risk of conversion of 19.2% (95% CI, 14.1%-24.0%). In multivariate analysis, age younger than 37 years (hazard ratio [HR], 4.04 [95% CI, 2.00-8.15]; P < .001), spinal cord lesions (HR, 5.11 [95% CI, 1.99-13.13]; P = .001), and gadolinium-enhancing lesions on index scan (HR, 2.09 [95% CI, 1.13-3.87]; P = .02) were independently associated with an increased risk of conversion to MS. Having 2 factors at the time of the index MRI scan was associated with a risk of 27.9% (95% CI, 13.5%-39.9%) of a seminal event within 2 years, increasing to 90.9% (95% CI, 41.1%-98.6%) for individuals with all 3 factors (3 risk factors vs none HR, 23.34 [95% CI, 9.08-59.96]; P < .001). Overall, with 80% power to detect an effect size of 60% within 24 months, a total of 160 individuals with RIS were needed assuming an event rate of 20%. Conclusions and Relevance This study found that age younger than age 37 years, spinal cord involvement, and gadolinium-enhancing lesions on index MRI scan were associated with earlier clinical disease and relevant to the number of enrolled patients needed to detect a potential treatment effect.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: JAMA Netw Open Año: 2021 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: JAMA Netw Open Año: 2021 Tipo del documento: Article País de afiliación: Francia